HomeCompareORXOY vs MO

ORXOY vs MO: Dividend Comparison 2026

ORXOY yields 71.43% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORXOY wins by $1.04M in total portfolio value
10 years
ORXOY
ORXOY
● Live price
71.43%
Share price
$2.80
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.12M
Annual income
$299,297.66
Full ORXOY calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — ORXOY vs MO

📍 ORXOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORXOYMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORXOY + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORXOY pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOY
Annual income on $10K today (after 15% tax)
$6,071.43/yr
After 10yr DRIP, annual income (after tax)
$254,403.01/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, ORXOY beats the other by $228,767.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOY + MO for your $10,000?

ORXOY: 50%MO: 50%
100% MO50/50100% ORXOY
Portfolio after 10yr
$601.8K
Annual income
$164,728.41/yr
Blended yield
27.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ORXOY
No analyst data
Altman Z
-0.1
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOY buys
0
MO buys
0
No recent congressional trades found for ORXOY or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORXOYMO
Forward yield71.43%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$1.12M$80.1K
Annual income after 10y$299,297.66$30,159.17
Total dividends collected$960.2K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ORXOY vs MO ($10,000, DRIP)

YearORXOY PortfolioORXOY Income/yrMO PortfolioMO Income/yrGap
1← crossover$17,843$7,142.86$10,570$780.30+$7.3KORXOY
2$31,003$11,911.12$11,381$1,032.90+$19.6KORXOY
3$52,515$19,342.29$12,535$1,392.73+$40.0KORXOY
4$86,812$30,620.19$14,193$1,920.91+$72.6KORXOY
5$140,194$47,305.90$16,618$2,723.68+$123.6KORXOY
6$221,406$71,397.66$20,263$3,993.80+$201.1KORXOY
7$342,284$105,380.00$25,936$6,098.36+$316.3KORXOY
8$518,499$152,255.26$35,166$9,775.01+$483.3KORXOY
9$770,345$215,550.93$51,026$16,597.78+$719.3KORXOY
10$1,123,567$299,297.66$80,113$30,159.17+$1.04MORXOY

ORXOY vs MO: Complete Analysis 2026

ORXOYStock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOY Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ORXOY vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOY vs SCHDORXOY vs JEPIORXOY vs OORXOY vs KOORXOY vs MAINORXOY vs PMORXOY vs BTIORXOY vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.